Into the era of mycobiome-driven cancer research

Weici Liu; Zheshun Pi; Ning-Ning Liu; Wenjun Mao

doi:10.1016/j.trecan.2024.02.009

Into the era of mycobiome-driven cancer research

Trends Cancer. 2024 Mar 16:S2405-8033(24)00047-5. doi: 10.1016/j.trecan.2024.02.009. Online ahead of print.

Authors

Weici Liu¹, Zheshun Pi¹, Ning-Ning Liu², Wenjun Mao³

Affiliations

¹ Department of Thoracic Surgery, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi 214023, Jiangsu, China; Wuxi College of Clinical Medicine, Nanjing Medical University, Wuxi 214023, Jiangsu, China.
² State Key Laboratory of Systems Medicine for Cancer, Center for Single-Cell Omics, School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China. Electronic address: liuningning@shsmu.edu.cn.
³ Department of Thoracic Surgery, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi 214023, Jiangsu, China; Wuxi College of Clinical Medicine, Nanjing Medical University, Wuxi 214023, Jiangsu, China. Electronic address: maowenjun1@njmu.edu.cn.

PMID: 38494372
DOI: 10.1016/j.trecan.2024.02.009

Abstract

The cancer mycobiome has recently become a research hotspot. While the intratumor mycobiota is implicated in cancer initiation and progression, the gut mycobiota functions as biomarkers for cancer diagnosis and treatment. In this forum article we highlight the involvement of the mycobiome in correlation-, causation-, and prediction-oriented cancer research and discuss the potential of this burgeoning field.

Keywords: cancer mycobiome; gut mycobiota; intratumor mycobiota.